See Anual Report 2024

See Anual Report 2023

See Anual Report 2022

The Risk of Infections Associated With JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Network Meta-analysis

Alves C, Penedones A, Mendes D, Batel-Marques F.

J Clin Rheumatol . 2021 Apr 24. doi: 10.1097/RHU.0000000000001749

2021

https://journals.lww.com/jclinrheum/Abstract/9000/The_Risk_of_Infections_Associated_With_JAK.98358.aspx

Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital

Mendes D, Abrantes J, Rigueiro G, Pais AF, Penedones A, Alves C, Batel Marques F.

J Oncol Pharm Pract. 2020 Sep 16;1078155220957079. doi: 10.1177/1078155220957079.

2020

https://journals.sagepub.com/doi/10.1177/1078155220957079?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Rectus sheath hematoma in patients receiving subcutaneous enoxaparin: A case series of five patients

Mendes D, Penedones A, Martins M, Cavadas S, Alves C, Batel Marques F.

Clin Case Rep. 2020; 00: 1– 8. https://doi.org/10.1002/ccr3.3427.

2020

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752400/pdf/CCR3-8-3432.pdf

A Systematic Review of Economic Studies Evaluating Ophthalmic Drugs: An Analysis of the Health-state Utilities

Inês Ribeiro, Francisco Batel Marques , Diogo Mendes, Carlos Alves

Ophthalmic Epidemiology; doi:10.1080/09286586.2020.1792938

2020

Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis.

Mendes D, Oliveira AR, Alves C, Batel Marques F.

Expert Opinion on Drug Safety; DOI: 10.1080/14740338.2020.1743262

2020

Recommendations to conduct and report systematic reviews in medical literature: a scoping review.

Penedones A, Alves C, Batel Marques F.

BMC Med Res Methodol. 2019;19(1):234

2019

Safety of Oral Antidiabetics: A Disproportionality Analysis in the Portuguese Pharmacovigilance System.

Mendes D, Alves C, Batel Marques F.

Revista Portuguesa de Farmacoterapia. 2019;11:84-94. https://doi.org/10.25756/rpf.v11i2-3.217

2019